MMMohammad Moniruzzaman

Mohammad Moniruzzaman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohammad Moniruzzaman has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Predictive Modelling for Early Detection of Type 2 Diabetes Using AI-Driven Machine Learning Algorithms and Big Data Analytics

    by Mia Md Tofayel Gonee Manik, Abu Saleh Muhammad Saimon, Kamal Ahmed, Sazzat Hossain, Mohammad Moniruzzaman, Shafiqul Islam


  • Big Data Analytics for Credit Risk Assessment

    by Mia Md Tofayel Gonee Manik, Abu Saleh Muhammad Saimon, Shafiqul Islam, Mohammad Moniruzzaman, Evha Rozario, Ekrim Hossin

    This project focuses on utilizing big data analytics in the banking sector to aid in decision-making processes, particularly in assessing the creditworthiness of loan applicants. By employing machine learning algorithms such as Decision Trees and Random Forests, the project aims to develop predictive models to identify trustworthy customers, thereby minimizing financial risks for banks. Python, PySpark, and Jupyter Notebook are utilized for data preprocessing, analysis, and model development. The project workflow involves data cleaning, exploration analysis, model building, and evaluation. Banks can make data-driven decisions to optimize their loan approval processes through this approach.


  • Open Access

    Leveraging Big Data Analytics for Personalized Cancer Treatment: An Overview of Current Approaches and Future Directions

    by Kamal Ahmed, Evha Rozario, Sraboni Clara Mohonta, Jannatul Ferdousmou, Abu Saleh Muhammad Saimon, Mohammad Moniruzzaman, Mia Md Tofayel Gonee Manik, Rakibul Hasan

    Big data analytics’ incorporation into customized cancer care is a revolutionary development in medical science. Using knowledge from genomic sequencing, electronic health records (EHRs), clinical trial databases, and social determinants of health, this systematic review investigates the relationship between artificial intelligence (AI), machine learning, and big data analysis in customizing cancer treatments for each patient. The study highlights how AI‐driven prediction models might improve treatment outcomes, reduce side effects, and increase patient safety by synthesizing insights from the last 10 years of academic research. A systematic literature review that follows PRISMA guidelines and includes both quantitative and qualitative evaluations of academic publications is among the key approaches. The findings show that multiomics approaches, which combine transcriptomics, proteomics, metabolomics, and genomics, are becoming increasingly important for customized medicine. Real‐time data analytics and wearable technology are also noted as promising resources for prompt responses. Notwithstanding obstacles, including data heterogeneity, moral dilemmas, and validation problems, the results highlight how crucial AI is to treating tumor complexity and developing precision medicine. In order to improve regulatory frameworks, promote interdisciplinary collaboration, and optimize AI applications in cancer treatment planning, the study concludes by suggesting future research areas. For scientists, physicians, and legislators hoping to transform cancer treatment using big data analytics–driven tailored medicine, this review provides insightful information.